Valosin Containing Protein as a Specific Biomarker for Predicting the Development of Acute Coronary Syndrome and Its Complication.
Valosin Containing Protein as a Specific Biomarker for Predicting the Development of Acute Coronary Syndrome and Its Complication.
复制标题
含有 Valosin 的蛋白质作为预测急性冠状动脉综合征及其并发症发展的特异性生物标志物
DOI：
10.3389/fcvm.2022.803532
复制
发表时间：
2022
影响因子：
3.6
通讯作者：
Li L
中科院分区：
文献类型：
--
作者：
Xu C;Yu B;Zhao X;Lin X;Tang X;Liu Z;Gao P;Ge J;Wang S;Li L
急性冠状动脉综合征（ACS）由一系列急性心肌缺血相关表现组成。 ACS 的不良事件通常与心室功能障碍 (VD) 相关，最终可能发展为心力衰竭。目前尚无令人满意的指标能够特异性预测ACS的发生发展及其预后。最近有人提出，含有 Valosin 的蛋白质（VCP）可以预防心脏病。因此，我们的目的是评估血清中的 VCP 是否可以作为预测 ACS 及其并发症的有价值的生物标志物。收集了 291 名参与者的人血清样本，并根据临床诊断分为四组，即健康对照 (n = 64)、ACS (n = 40)、慢性冠状动脉综合征 (CCS，n = 99) 和非缺血性心脏病 (非 IHD，n = 88)。记录这些参与者的临床特征，并通过酶联免疫吸附测定（ELISA）检测他们的血清VCP水平。对血清 VCP 与 ACS 及其并发症 VD 发生的关系进行了统计学研究。随后，进行了 GWAS 和 eQTL 分析，以探讨 VCP 多态性与单核细胞计数之间的关联。还进行了稳定性测试，以研究 VCP 是否是稳定的生物标志物。与其余组相比，ACS 组的血清 VCP 水平显着升高。此外，伴有VD的ACS患者的VCP水平显着低于无VD的患者。多变量逻辑回归分析显示，VCP 与 ACS 风险（P = 0.042，OR = 1.222）和 ACS 患者发生 VD 的风险（P = 0.035，OR = 0.513）独立相关。 GWAS分析还确定了VCP多态性（rs684562）与单核细胞计数之间的关联，而rs684562对VCP mRNA表达水平的影响通过eQTL分析进一步验证。此外，在不同保存环境下，血清VCP含量具有较高的稳定性。含有 Valosin 的蛋白可以作为预测 ACS 及其并发症 VD 发展的稳定生物标志物。
Acute coronary syndrome (ACS) consists of a range of acute myocardial ischemia-related manifestations. The adverse events of ACS are usually associated with ventricular dysfunction (VD), which could finally develop to heart failure. Currently, there is no satisfactory indicator that could specifically predict the development of ACS and its prognosis. Valosin-containing protein (VCP) has recently been proposed to protect against cardiac diseases. Hence, we aimed to assess whether VCP in serum can serve as a valuable biomarker for predicting ACS and its complication. Human serum samples from 291 participants were collected and classified into four groups based on their clinical diagnosis, namely healthy control (n = 64), ACS (n = 40), chronic coronary syndrome (CCS, n = 99), and nonischemic heart disease (non-IHD, n = 88). Clinical characteristics of these participants were recorded and their serum VCP levels were detected by enzyme-linked immunosorbent assay (ELISA). Association of serum VCP with the development of ACS and its complication VD was statistically studied. Subsequently, GWAS and eQTL analyses were performed to explore the association between VCP polymorphism and monocyte count. A stability test was also performed to investigate whether VCP is a stable biomarker. Serum VCP levels were significantly higher in the ACS group compared with the rest groups. Besides, the VCP levels of patients with ACS with VD were significantly lower compared to those without VD. Multivariate logistic regression analysis revealed that VCP was associated with both the risk of ACS (P = 0.042, OR = 1.222) and the risk of developing VD in patients with ACS (P = 0.035, OR = 0.513) independently. The GWAS analysis also identified an association between VCP polymorphism (rs684562) and monocyte count, whereas the influence of rs684562 on VCP mRNA expression level was further verified by eQTL analysis. Moreover, a high stability of serum VCP content was observed under different preservation circumstances. Valosin-containing protein could act as a stable biomarker in predicting the development of ACS and its complication VD.